Where does Celgene CAR LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Celgene CAR LLC ranks #7,388 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Celgene CAR LLC hold?

Celgene CAR LLC holds 44 US utility patents granted between 2017 and 2023, spanning 13 technology areas.

What is Celgene CAR LLC's Innovation Score?

Celgene CAR LLC has an Innovation Score of 39.8 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Celgene CAR LLC focus on?

Celgene CAR LLC's top technology area is C07D (Heterocyclic Compounds) with 44 patents, ranking #189 of 3,165 assignees active in that subclass. Grants appear in 13 CPC subclasses total.

Is Celgene CAR LLC's patent grant rate increasing or decreasing?

Celgene CAR LLC's recent grant velocity is -9% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Celgene CAR LLC's patents?

Celgene CAR LLC's patents average 18.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Celgene CAR LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Celgene CAR LLC

USPTO PatentsView assignee record - 44 granted patents across 13 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Celgene ranks #7,388 of 49,997 tracked US assignees by granted-patent volume, with 44 patents across 13 technology areas.

#7,388
of 49,997 US assignees by volume: Top 37%
by Innovation Score (39.8/100): 18.9
avg claims per patent: -9%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7388 · Foreign Corporation #7,388 · 44 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 44 grants
UPPER-Q #7,388/49,997
PHOTO-FINISH Cattron North America
CPC-FOCUS C07D · 13 areas
INNOV-THIN 39.8/100
CLAIMS-RICH 18.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT -9% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cattron North America, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Celgene’s 39.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.1 pts (33%) Velocity 2.6 pts (7%) Breadth 12.7 pts (32%) Claim depth 11.3 pts (28%)

Qualcomm Incorporated · highest

85
Annex Products PTY · near

40
Celgene CAR · this assignee

40
Grey Orange PTE · near

40
Arashi Vision · near

40
Nok Nok Labs · near

40
3D Lighting… · lowest

7

What this shows Celgene's Innovation Score is 39.8/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Celgene?

Each dot is one of Celgene’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Celgene’s own 18.9 claims/patent is ABOVE the 17.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Celgene vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Celgene's grants concentrate

Celgene CAR LLC is a focused PatentsView assignee: 13 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2018 (11 grants) versus a trough of 3 in 2022. By volume, Celgene sits between Consolidated Edison Company OF NEW York, Inc. and Corel Corporation.

Celgene's three-year grant acceleration

Celgene CAR LLC shows 7 grants in 2022–2024 against only 18 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Consolidated Edis…

44
Coretech System

44
Cattron North Ame…

44
Celera

44
Certainteed Ceili…

44
Commscope Connect…

44
Compugen

44
Corel

44
Celgene CAR ◀

44

What this shows Celgene holds 44 patents at rank #7,390, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Celgene

By rank, the assignees closest to #7,390 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Celgene's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Celgene, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Celgene ranks #189 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Annex Products PTY Ltd 40 Grey Orange PTE. Ltd. 40 Arashi Vision Inc. 40 Nok Nok Labs, Inc. 40

Celgene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Celgene CAR LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	8	18.2%
2018	11	25.0%
2019	4	9.1%
2020	7	15.9%
2021	7	15.9%
2022	3	6.8%
2023	4	9.1%

Which technologies does Celgene CAR LLC patent most?

C07D - Heterocyclic Compounds 44

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 37

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 28

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 11

C12Y - Enzymes 9

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C07C - Acyclic OR Carbocyclic Compounds 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C07K - Peptides 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

G16C - Computational CHEMISTRY; CHEMOINFORMATICS; Computational Materials Science 1

Top 13 of 13 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Celgene CAR LLC's patent record in context - here's where to go next.

Celgene CAR LLC's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #7,388 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Celgene CAR LLC against Consolidated Edison Company OF NEW York, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.